Abstract
Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. All four patients had been taking high doses of niacin (3.0-4.5 g daily) before the onset of symptoms. An additional 15 asymptomatic patients who were receiving high doses of oral niacin (1.0-6.0 g daily) for the treatment of hypercholesterolemia were evaluated for evidence of subclinical macular disease. None of these patients had cystic or other significant macular changes. Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug. The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 930-936 |
| Number of pages | 7 |
| Journal | Ophthalmology |
| Volume | 95 |
| Issue number | 7 |
| State | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Niacin maculopathy. / Millay, R. H.; Klein, Michael; Illingworth, D. R.
In: Ophthalmology, Vol. 95, No. 7, 1988, p. 930-936.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Niacin maculopathy
AU - Millay, R. H.
AU - Klein, Michael
AU - Illingworth, D. R.
PY - 1988
Y1 - 1988
N2 - Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. All four patients had been taking high doses of niacin (3.0-4.5 g daily) before the onset of symptoms. An additional 15 asymptomatic patients who were receiving high doses of oral niacin (1.0-6.0 g daily) for the treatment of hypercholesterolemia were evaluated for evidence of subclinical macular disease. None of these patients had cystic or other significant macular changes. Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug. The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.
AB - Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. All four patients had been taking high doses of niacin (3.0-4.5 g daily) before the onset of symptoms. An additional 15 asymptomatic patients who were receiving high doses of oral niacin (1.0-6.0 g daily) for the treatment of hypercholesterolemia were evaluated for evidence of subclinical macular disease. None of these patients had cystic or other significant macular changes. Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug. The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.
UR - http://www.scopus.com/inward/record.url?scp=0023943812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023943812&partnerID=8YFLogxK
M3 - Article
C2 - 3174043
AN - SCOPUS:0023943812
VL - 95
SP - 930
EP - 936
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 7
ER -